December 5-8, 2022 | Boston, MA

With systemic toxicity challenges plaguing the AAV field, direct administration for CNS indications creates an ideal target for gene therapy.

This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets.

Across 2 dedicated tracks of content, this physical meeting will host the fields leading industry scientists and neurosurgeons to cover:

• Comparing different case studies of administration route from intrathecal, intra cisterna magna and direct injection into the CNS
• Evaluating the dosage and distribution challenges of translating from rodents into NHPs and humans
• Discovering novel AAV, lentiviral and non-viral vectors for CNS specificity

And much, much more.

Join the expanding audience of gene therapy experts seeking to overcome the translational hurdles of developing gene therapies for CNS targets, from discovery, preclinical, translational, clinical, and commercial departments at the likes of Capsigen, AviadoBio, AskBio, Novartis, Prevail Therapeutics, Passage Bio, Voyager Therapeutics,UniQure and more.

Register today to join us in Boston this December.